Press releases
US-specific press releases are available here. Please visit our global website for access to global press releases dating back to 2009
-
GSK awards Greater Philadelphia nonprofits making a dynamic IMPACT on health outcomes
GSK awards Greater Philadelphia nonprofits making a dynamic IMPACT on health outcomes
Read more -
GSK announces $1 million grant to protect children in North Carolina, Puerto Rico from disaster
GSK announces $1 million grant to protect children in North Carolina, Puerto Rico from disaster
Read more -
GSK awards Triangle nonprofits making a dynamic IMPACT on health outcomes
Ten nonprofits will each receive $40,000 to support life coaching and mentorship, healthy eating, literacy, the comforts of home and other social determinants of health.
Read more -
Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation.
Read more -
GSK delivers Q3 sales of £8.1 billion, +3% AER, +6% CER
Total EPS 28.8p, +16% AER, +23% CER; Adjusted EPS 35.5p, +10% AER, + 14% CER
Read more -
GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
Marked patient benefit observed in phase II study supports further clinical development of GSK3196165 for RA.
Read more -
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
Read more -
Positive results from Harmony Outcomes study of albiglutide published in The Lancet (1)
GSK and the Duke Clinical Research Institute (DCRI) today announced publication of positive results from the Harmony Outcomes study which assessed the cardiovascular (CV) safety...
Read more -
GSK updates policy for working with healthcare professionals
We are updating our policy on working with healthcare professionals (HCPs).
Read more -
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
Positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions
Read more -
GSK and Tres Cantos Open Lab Foundation announce additional £5m funding for open innovation research in diseases impacting the developing world
Additional £5m in GSK funding to support the Foundation’s research and development programmes in diseases of the developing world.
Read more -
Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone fu...
Read more -
ViiV Healthcare submits regulatory application to European Medicines Agency for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of doluteg...
Read more -
GSK data presented at ERS further supports its industry-leading respiratory medicines portfolio
GlaxoSmithKline plc (GSK) will profile the growing evidence base that supports its broad respiratory medicines portfolio at the European Respiratory Society (ERS) congress in Pa...
Read more -
GSK announces results of indirect treatment comparisons of Nucala to benralizumab and reslizumab for severe eosinophilic asthma
Nucala demonstrated greater reduction in exacerbations and improved asthma control.
Read more -
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc (LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab as an add-on treatment to inhaled c...
Read more -
European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
First anti-IL-5 biologic treatment for paediatric patients with severe eosinophilic asthma in Europe
Read more -
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen
ATLAS study meets primary endpoint, showing similar efficacy of a once-a-month, investigational, injectable two-drug regimen of cabotegravir and rilpivirine compared to a standa...
Read more -
GSK ships 2018-19 seasonal influenza vaccines for US market
GSK today announced it will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2018-19 flu season, immediately following licens...
Read more -
Iain Mackay appointed GSK Chief Financial Officer
GSK today announced that Iain Mackay has been appointed GSK’s next CFO.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
